On the contrary, CLL samples with TP53 defects exhibited variable sensitivity to MDM2 inhibitors depending on the nature of the TP53 aberration and the proportion of CLL cells harboring it, with loss of p53 function correlating strongly with diminished sensitivity to MDM2 inhibition [53,55,56]. Here, MDM2 is linked to B-cell chronic lymphocytic leukemia.